A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

(2016) Priyanka A. Pophali et al.   CANCER JOURNAL

A review of the European LeukemiaNet recommendations for the management of CML

(2015) Michele Baccarani et al.   ANNALS OF HEMATOLOGY

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

(2015) Jorge E. Cortes et al.   CANCER

Allogeneic transplantation for CML in the TKI era: striking the right balance

(2015) Andrew J. Innes et al.   Nature Reviews Clinical Oncology

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses

(2015) M Wetzler et al.   Blood Cancer Journal

Chronic Myeloid Leukemia–Transplantation in the Tyrosine Kinase Era

(2014) Andrew J. Innes et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Homoharringtonine and omacetaxine for myeloid hematological malignancies

(2014) Shuqing Lü et al.   Journal of Hematology & Oncology

Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate

(2014) A. Q. Shen et al.   ONCOLOGIST

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

(2013) J. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib

(2013) Jorge E. Cortes et al.   Clinical Lymphoma Myeloma & Leukemia

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia

(2013) T. Lange et al.   HAEMATOLOGICA

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

(2013) F. E. Nicolini et al.   HAEMATOLOGICA

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia

(2013) F. Alvandi et al.   ONCOLOGIST

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

(2012) J. Cortes et al.   BLOOD

Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

(2012) Xuelin Huang et al.   CANCER

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

(2012) John Nemunaitis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

(2011) Elias Jabbour et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

(2011) Carlo Gambacorti-Passerini et al.   JNCI-Journal of the National Cancer Institute

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

(2011) E K Allan et al.   LEUKEMIA

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

(2010) E. Jabbour et al.   BLOOD

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

(2010) A. R. Ibrahim et al.   BLOOD

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

(2010) H. M. Kantarjian et al.   BLOOD

The Durable Clearance of the T315I BCR-ABL Mutated Clone in Chronic Phase Chronic Myelogenous Leukemia Patients on Omacetaxine Allows Tyrosine Kinase Inhibitor Rechallenge

(2010) Franck E. Nicolini et al.   Clinical Lymphoma Myeloma & Leukemia

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

(2009) R. J. Garg et al.   BLOOD

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

(2009) Alfonso Quintás-Cardama et al.   CANCER

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

(2009) D. Milojkovic et al.   HAEMATOLOGICA

U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:

(2009) Güliz Gürel et al.   JOURNAL OF MOLECULAR BIOLOGY

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA